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AbstrAct
Introduction Adrenal incidentalomas are lesions that are 
incidentally identified while scanning for other conditions. 
While most are benign and hormonally non- functional, 
around 20% are malignant and/or hormonally active, 
requiring prompt intervention. Malignant lesions can 
be aggressive and life- threatening, while hormonally 
active tumours cause various endocrine disorders, 
with significant morbidity and mortality. Despite this, 
management of patients with adrenal incidentalomas is 
variable, with no robust evidence base. This project aimed 
to establish more effective and timely management of 
these patients.
Methods We developed a web- based, electronic Adrenal 
Incidentaloma Management System (eAIMS), which 
incorporated the evidence- based and National Health 
Service–aligned 2016 European guidelines. The system 
captures key clinical, biochemical and radiological 
information necessary for adrenal incidentaloma patient 
management and generates a pre- populated outcome 
letter, saving clinical and administrative time while 
ensuring timely management plans with enhanced safety. 
Furthermore, we developed a prioritisation strategy, 
with members of the multidisciplinary team, which 
prioritised high- risk individuals for detailed discussion 
and management. Patient focus groups informed process- 
mapping and multidisciplinary team process re- design and 
patient information leaflet development. The project was 
partnered by University Hospital of South Manchester to 
maximise generalisability.
Results Implementation of eAIMS, along with 
improvements in the prioritisation strategy, resulted in 
a 49% reduction in staff hands- on time, as well as a 
78% reduction in the time from adrenal incidentaloma 
identification to multidisciplinary team decision. A health 
economic analysis identified a 28% reduction in costs.
Conclusions The system’s in- built data validation and 
the automatic generation of the multidisciplinary team 
outcome letter improved patient safety through a reduction 
in transcription errors. We are currently developing the 
next stage of the programme to proactively identify all new 
adrenal incidentaloma cases.
Problem
Adrenal incidentalomas are lesions inciden-
tally detected during abdominal imaging 
for other disorders. While most are benign, 
3%–6% are malignant, rapidly progressive 
and life threatening. A further 12%–15% 
are hormonally active (including Cushing’s 
syndrome, phaeochromocytoma and Conn’s 
disease), with significant morbidity and 
mortality (eg, diabetes, uncontrolled hyper-
tension, sudden death). Management of 
patients with adrenal incidentalomas and the 
approach to their investigation and follow- up 
are variable, both within and between centres. 
This often leads to overinvestigation (wasting 
National Health Service (NHS) resources) 
and underdiagnosis (missing potentially 
life- threatening lesions) and can result in 
extended delays in diagnosis and treatment. 
This variability in testing can lead to delays 
in treatment, which may result in a lack of 
patient engagement. This lack of engage-
ment reduces patients’ understanding of the 
process, further increasing their anxiety.1
CT and MRI scan requests are being increas-
ingly incorporated into diagnostic pathways. 
At University Hospitals of North Midlands 
NHS Trust, the number of abdominal CT 
scans has increased fourfold, exceeding 
12 000 per annum over the last 6 years. There 
was a similar trend at our partner, the Univer-
sity Hospital of South Manchester Foun-
dation Trust. Consequently, more adrenal 
incidentalomas are being identified. With 
a reported incidence of 4% in radiological 
studies,2 400–500 cases are identified annu-
ally for both our centres, 20% of which are 
potentially functional or malignant.3 This 
equates to an estimated total UK incidence 
of around 50 000 new adrenal incidentalomas 
annually (of which 1500 will be malignancies 
and 6000 will be functional lesions).
The sheer volume of cases is extremely diffi-
cult for any health system to cope with. If all 
these cases are proactively evaluated, as they 
should be, this would be equivalent to 25% 
of University Hospitals of North Midlands’ 
total block contract for new endocrinology 
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referrals. These are presently not accounted for within 
the contract, despite 20% being potentially hormonally 
active or malignant.
Despite University Hospitals of North Midlands having 
a dedicated multidisciplinary team, initial data showed 
the median time (and IQR) between the patient receiving 
the radiological scan and multidisciplinary team deciding 
how to treat the patient was 6.00 (4.00–9.00) months. The 
median number of patient visits was 4.00 (3.00–4.25) and 
the median number of letters generated was 7.00 (5.50–
8.50). Centres with no multidisciplinary team will likely 
have longer delays between scan and treatment decision 
and involve more patient letters and visits.
Given the above, adrenal incidentalomas are a major 
challenge, requiring an urgent and unified approach.1 4 
We therefore decided to undertake a quality improvement 
project to better manage these patients, including devel-
oping a new adrenal multidisciplinary team process and 
electronic patient management system (eAIMS). We 
aimed to improve clinical safety around management of 
patients with adrenal incidentaloma, to reduce the time 
from initial identification of the adrenal incidentaloma 
to multidisciplinary team decision, and also to enhance 
cost- effectiveness. We also wanted to proactively identify 
all adrenal incidentaloma cases and optimise these into 
high- risk or low- risk categories to ensure that treatment 
was received at the appropriate level and speed.
background
The significant variability in the approach to treating 
patients with adrenal incidentalomas stems from the fact 
that there were no UK NHS- compatible guidelines for 
managing the condition. Guidance has limited utility, 
as highlighted in a NHS report confirming that adrenal 
incidentalomas are a common clinical dilemma and the 
majority of affected patients are inappropriately investi-
gated.5
A recent literature review (using search terms including 
‘adrenal incidentaloma management’ and ‘adrenal inci-
dentaloma guidance’) indicated that US/European 
guidelines have been largely based on retrospective, 
limited and often conflicting data relating to thresholds 
and timelines for planning investigations.6 7 NHS manage-
ment plans are not driven by insurers or fee- for- service 
payments (unlike US/European- based systems), limiting 
the relevance of these guidelines to the UK.
A study from a UK district general hospital identified 
75 patients with adrenal incidentalomas in 2010.5 The 
majority (80%) received no biochemical investigation 
or follow- up, with only 13 (17%) referred for specialist 
review and two further patients undergoing additional 
evaluation in primary care. A further UK study, focusing 
on biochemical investigations, accepted that, for patients 
with adrenal incidentaloma, ‘Their best management strategy 
is unknown’.8 The medical literature emphasises inter-
national acknowledgement that these tumours pose a 
management dilemma,9 but there is no NHS- compatible 
system to ensure appropriate management.
In summary, these studies highlight the lack of consensus 
regarding adrenal incidentaloma management. There 
is a risk of missing serious conditions that could be life 
threatening (including phaeochromocytoma and excess 
cortisol production) and that require rapid intervention. 
Many patients who ultimately do not require further 
follow- up need appropriate and timely investigation and 
effective communication to avoid unnecessary distress.
Our proposal, therefore, aimed to combine the new 
NHS- compatible European adrenal incidentaloma guide-
lines with information technology (IT) infrastructure and 
NHS- based referral processes to establish the first stream-
lined, clinically effective, patient- centred electronic 
Adrenal Incidentaloma Management System (eAIMS). 
This is highly innovative because it is
 ► Evidence- based: eAIMS uses newly developed guide-
lines appropriate for integration into NHS processes 
(acknowledging the magnitude of the problem, 
referral processes and patient safety).
 ► Multidisciplinary: Involving all key stakeholders 
(patients, commissioners, radiologists, clinical 
biochemists, hospital IT and Service Transformation 
experts as well as acute hospital physicians) in the 
design and evaluation from the outset.
 ► Patient- orientated: Engaging patients in designing 
eAIMS (eg, steps followed in investigating and 
communicating results) and development of informa-
tion leaflets. Patients will also help in evaluation via a 
survey of impact on anxiety.
 ► Embedded: By involving IT experts and Service Trans-
formation teams, this System will be embedded into 
routine clinical pathways for adrenal incidentaloma 
management.
 ► Efficient: Exploiting IT to establish an integrated 
management system to facilitate interaction between 
the different steps and specialists in the pathway, 
ensuring timely investigations, multidisciplinary team 
interpretations, and communication with patients 
and general practitioners.
 ► Cost- effective: Eliminating unnecessary investigations, 
outpatient visits and interventions10 (independently 
evaluated by University of East Anglia).
 ► Generalisable: By selecting two sites with differing 
demographic populations and approaches to adrenal 
incidentaloma management, the potential for roll- out 
across the wider NHS is more assessable.
 ► Addressing an unmet need: There is currently no system 
to address this gap in proactively managing patients 
with adrenal incidentalomas.
measuremenT
Despite the advantage of University Hospitals of North 
Midlands having their own dedicated multidisciplinary 
team, our own initial data showed that the median (IQR) 
time between the patient having their radiological scan 
and multidisciplinary team decision on how to treat that 
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patient was 6.00 (4.00–9.00) months, the median number 
of patient visits was 4.00 (3.00–4.25) and the median 
number of letters generated (sent to the patient or his or 
her general practitioner or the referrer) was 7.00 (5.50–
8.50).
Our outcome measures (for the current study) were as 
follows:
Primary
Time from initial radiological detection to multidisciplinary team 
decision
We aimed to reduce the median time from initial radio-
logical detection of the adrenal incidentaloma to multi-
disciplinary team decision by 20% (from 6.00 to 4.75 
months based on University Hospitals of North Midlands 
data).
Two additional or secondary measures focused on 
safety aspects of adrenal incidentaloma patient manage-
ment. The first of these was a reduction in the number 
of functional tumours missed or not actioned, compared 
with retrospective audit data. The second was a reduc-
tion in the number of malignant tumours missed or not 
actioned.
Process measures
The time taken from initial identification of an adrenal 
incidentaloma to a multidisciplinary team decision was 
expected to be shorter and less variable compared with 
the current practice. It was possible to break this part of 
the patient pathway down into five component parts or 
stages. The first is the time taken from the date an adrenal 
incidentaloma is identified to electronic referral to a 
consultant. The second stage is the time from this referral 
to a patient clinic appointment date. The third stage is 
the time from this clinic appointment to the resulting 
tests being completed (ie, results known). From this, the 
fourth stage is the time until the patient is reviewed at 
a multidisciplinary team meeting. The final stage is the 
time from multidisciplinary team discussion to the multi-
disciplinary team decision.
design
course of intervention
The intervention was developed through four distinct, 
interlinked processes. First, we re- designed the adrenal 
incidentaloma pathway. This was achieved by developing 
a prioritisation strategy, in collaboration with the radi-
ology and biochemistry multidisciplinary team members. 
This ensured that high- risk individuals were prioritised 
for detailed prompt discussions, while streamlining the 
process for low- risk cases. These were classified in accord-
ance with European guidelines. For example, lipid- rich 
lesions on scanning, with no evidence of excess hormone 
production, were considered low- risk while those with 
evidence of excess hormone production and/or lipid- 
poor (or expanding) lesions were considered as high- risk. 
Patients with a risk of malignancy were fast- tracked for 
discussion at the next multidisciplinary team meeting, in 
line with the UK ‘2- week wait’ principles.
Next, we developed the eAIMS. This was done in collab-
oration with University Hospital of South Manchester and 
the IT teams at both NHS Trusts. This system captures 
the key information on all adrenal incidentaloma cases 
and generates a pre- populated outcome letter, saving 
both clinical and administrative time and effort while 
ensuring a timely management plan with enhanced safety 
(achieved through reduced need to re- dictate and type 
results, minimising transcription errors). The system is 
also aligned with the newly published European Guide-
lines for adrenal incidentaloma management and uses 
the same prioritisation strategy as described above.
The third stage was to use data obtained from patients 
to inform the process- mapping and the re- design of the 
multidisciplinary team process. Patients also helped to 
develop a patient information leaflet.
Finally, we used our partnership with University Hospital 
of South Manchester to explore the generalisability of the 
utility of the system. The system was conceived as web- 
based from the outset to facilitate wider adoption. We also 
established dialogue with national professional bodies to 
showcase the work.
Primary and secondary data used
Initially, the time from radiological detection of the 
adrenal incidentaloma to multidisciplinary team decision 
on how to treat the patient was our primary outcome. 
However, while we were developing the eAIMS, we had 
to accommodate rising numbers of largely low- risk cases 
while promptly handling the urgent complex cases. 
Therefore, we upgraded our processes to include clinical 
prioritisation for multidisciplinary team case selection. 
This meant that we exceeded our target of speeding up 
the process, even before the eAIMS system was imple-
mented.
We therefore present data on the impact of these 
improvements on the time between identifying and 
making a decision on the nature of the adrenal inciden-
taloma, including any further management if needed. We 
also focus on three key benefits of the system, namely, 
safety, efficiency and cost- effectiveness.
The first of these identified benefits, safety, considered 
the proportion of patients currently being missed (iden-
tified by radiology as having an adrenal incidentaloma, 
but not referred for further evaluation). Using key terms, 
a database of CT scans with adrenal incidentalomas was 
created. A consultant radiologist and consultant endo-
crinologist reviewed the radiological and clinical data to 
identify those with genuine adrenal incidentalomas and 
the proportion referred for further evaluation. Based on 
expected prevalence data, we believed that most patients 
are missed.
The second benefit was improved efficiency, that is, the 
time taken, in terms of staff hands- on time, in processing 
each case. This was calculated based on discussion with the 
key staff who perform each step in the patients’ treatment 
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pathway (secretary, endocrinologist, biochemist, radiolo-
gist, multidisciplinary team staff).
The final identified benefit was cost- effectiveness. To 
determine cost- effectiveness, the above data were inde-
pendently assessed by a health economist to facilitate esti-
mation of the cost impact of the intervention.
sTraTegy
Team
This included the clinical teams (including members 
from endocrinology, clinical biochemistry and radiology, 
urology from the two hospitals) who worked closely with 
the IT (IT trust management team on both hospital sites 
together with the programmer) and the project team 
(including the clinical academics, project management, 
study methodologist as well as independent statistician 
and health economy teams) to ensure this project was 
conceived and implemented.
approach and organisation of intervention
The initiative was triggered by the observation that the 
workload emanating from management of adrenal inci-
dentalomas was escalating significantly. We also noted 
that the process included much repetition, wasting clin-
ical and administration time. The median time from 
detection to decision was also noted to be long in many 
cases, with many patients reporting anxiety and distress. 
Almost all had to resort to the internet for information, 
which compounded their uncertainty.
This led us to review the literature to assess current 
evidence on clinical management and process- related 
initiatives for these patients. We also reviewed the existing 
approach to managing adrenal incidentalomas, leading 
to a process mapping exercise. We then used stakeholder 
groups to develop a driver diagram to assist in the devel-
opment of the interventions. Finally, we developed a 
number of Plan- Do- Study- Act (PDSA) cycles as follows:
Pdsa cycle 1
We initially identified the main problem: that patients with 
newly diagnosed adrenal incidentaloma were waiting, on 
average, 6 months between initial identification of the 
lesion and multidisciplinary team decision.
We developed a prioritisation strategy based on avail-
able guidance to ensure patients with lesions requiring 
urgent attention (eg, cancer) will be given priority for 
discussion in the multidisciplinary team meeting. This 
was discussed and agreed among the team members.
Pdsa cycle 2
Faced with the ongoing pressure on the service from the 
process of managing adrenal incidentaloma referrals, 
with its impact on staff time and potential delay incurred, 
we created a driver diagram to assess the main reasons for 
this delay, which led to identification of ideas for change 
(figure 1).
We then held a focus group with patients who had 
been treated for adrenal incidentalomas to discuss our 
proposed ideas for change and our suggested approach. 
Importantly, the patients identified key elements in 
terms of timings in order to inform the generation of 
the new process map. For example, they identified that 
it was important to progress the laboratory investigations 
while awaiting a clinic appointment rather than waiting 
to be seen in the clinic before investigations were initi-
ated. The proposed new process map (figure 2) informed 
the specification for the development of the web- based 
eAIMS system. Patients were identified as low- risk based 
on the radiology report (lipid- rich and/or stable lesion 
in comparison with earlier scans) and functional status. 
The effectiveness of the eAIMS was assessed by (1) a time- 
and- motion study to evaluate hands- on time, and (2) a 
cost- effectiveness analysis.
During this process, it became clear that many adrenal 
incidentaloma cases may have not been referred to endo-
crinology (based on the disparity between the expected 
number and those actually referred). We therefore insti-
gated an assessment to determine the proportion of cases 
that were being missed. This required the collection of 
retrospective radiological data using ‘key phrases’ in the 
reports. It identified that a significant proportion of cases 
were being missed (see Results section).
Pdsa cycle 3
Given the ongoing dependence on CT and MRI scans, 
together with the increasing awareness of adrenal inci-
dentalomas, we became acutely aware of the inevitable 
increasing number of referrals. We are currently imple-
menting further change to allow the endocrinology 
team to manage the additional workload. This involves 
the development of a pre- multidisciplinary team stream-
lining process, which is based on the time and motion 
study and linked cost- effectiveness analysis. We have 
also involved patients to gauge their thoughts on how 
to provide support during the waiting process. While 
this allowed the development of a patient leaflet (with 
patient input), it is planned that this will eventually 
feed into the development of a patient portal within 
eAIMS. This will provide information for patients using 
frequently asked questions generated from a pool of 
existing patients.
challenges
During the project, we identified three key challenges. 
The first of these was the importance of being able to 
automatically generate letters via the eAIMS platform. 
While this was outside the original project’s plans, it was 
still prioritised and subsequently developed. Second, 
clinical and biochemical data are entered manually by 
a multidisciplinary team co- ordinator. We are currently 
enhancing the platform’s capability to interface with 
existing hospital systems in order to minimise manual 
data entry and hence reduce the risk of errors. Finally, 
the need for generalisability became obvious early in the 
project and hence we opted for a web- based solution.
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Figure 1 Driver diagram showing the main drivers to address the shortfalls in adrenal incidentaloma management, with 
potential solutions provided by the electronic Adrenal Incidentaloma Management System (eAIMS) and revised processes. MDT, 
multidisciplinary team.
resulTs
This study was designed to develop a new process for 
managing patients with adrenal incidentalomas. This 
comprised the development and testing of a novel digital 
solution followed by its evaluation and integration into 
clinical practice. These two components are described 
below.
eaims system development
We successfully developed eAIMS, including
1. Conceptualisation: Discussion among key stakehold-
ers to agree the system requirements and associated 
deliverables.
2. Specification development (with Trust IT collabora-
tion): Based on process mapping (figure 2) and discus-
sion with IT colleagues, the concepts were translated 
into an IT- compliant NHS system specification docu-
ment.
3. Prototype development: A Trust- assigned IT program-
mer translated the specification into an initial proto-
type, which was then subjected to several iterations 
based on ongoing discussions with the project team.
4. Information governance compliance assessment: As 
an integral part of ensuring information governance 
requirements were fulfilled, especially given the web- 
based nature of the product, the Trust Information 
Governance team were engaged to ensure compliance.
5. Technical testing and de- bugging: Following the de-
velopment of the initial prototype, a comprehensive 
and rigorous testing protocol was undertaken, using 
a series of testing scripts based on clinically relevant 
scenarios, to ensure optimum system performance.
6. Real- world system testing and revision: After complet-
ing IT- instigated assessments, the system was assessed 
using real patient data. This enabled identification 
of areas for improvement of data entry. This process 
included the key step of generating an automated 
multidisciplinary team outcome letter, enhancing the 
potential of the system to be scaled up and adopted at 
other centres.
7. Implementation. The system was implemented into 
clinical practice. A demonstration (with fictional pa-
tients) is available online (http:// mi. cx/ eaims- phase1- 
demo. mp4).
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Figure 2 Process map following risk stratification for (A) high- risk patients and (B) low- risk patients. eAIMS, electronic Adrenal 
Incidentaloma Management System; MDT, multidisciplinary team.
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Figure 3 Median time between adrenal incidentaloma identification and multidisciplinary team (MDT) decision, before and after 
electronic Adrenal Incidentaloma Management System (eAIMS) implementation.
Table 1 Adrenal incidentaloma cases referred to endocrinology
Nov 2014 Nov 2015 Nov 2016
Total cases reported using the index phrases 57 76 77
Previously known malignancies (excluded) 30 41 15
Confirmed adrenal incidentalomas 27 35 62
Adrenal incidentalomas referred 8 10 20
Percentage of adrenal incidentalomas referred 29.6% 28.6% 32.3%
eaims system and process evaluation
Our initial objective was to reduce the delay between 
adrenal incidentaloma identification and multidiscipli-
nary team decision by 20%, from 6 months (pre- project) 
to 4.8 months. As a result of this project, a stepwise reduc-
tion in this delay was observed as different elements of 
the programme were implemented, resulting in a mark-
edly greater reduction in the time to multidisciplinary 
team decision than originally anticipated. For example, 
introduction of the improved prioritisation of cases 
within the multidisciplinary team resulted in the median 
delay being reduced by 58.3% to 2.50 months (figure 3), 
while implementation of the eAIMS system reduced this 
further to 1.25 months (78.3% total reduction in delay).
balancing measure: proportion of missed adrenal 
incidentaloma cases
During the implementation of the eAIMS system and 
associated process redesign, it became clear that not all 
adrenal incidentaloma cases were being appropriately 
referred. We therefore assessed the proportion of these 
cases as a balancing measure. To evaluate this, data on 
adrenal lesions reported on CT scans were collected from 
2014 to 2016, focusing on the referral for the month of 
November each year as a representative sample (table 1).
Key phrases from radiology reports were used to 
identify cases linked to possible adrenal lesions. These 
included the terms Adrenal adenoma, Adrenal inciden-
taloma, Adrenal lesion, Adrenal mass, Adrenal nodule, 
Incidental adrenal and Indeterminate adrenal.
Patients with known cancer were excluded and those 
with genuine adrenal incidentalomas were then checked 
(based on multidisciplinary team note entry and/or 
review of endocrinology letters) to confirm whether or 
not they were acted on and were referred to endocri-
nology for further assessment.
Analysis showed that, despite having a dedicated multi-
disciplinary team and service, which is not routine prac-
tice in most centres in the UK and globally, only ~30% 
of cases were referred for evaluation. This means that 
even in the presence of a dedicated team and spreading 
knowledge, 70% of adrenal incidentalomas were being 
missed.
The eAIMS and prioritisation process will enable detec-
tion of these missed cases to be highlighted to referring 
clinicians and general practitioners. The additional work-
load would be circumvented by the implementation of 
the more efficient and streamlined process, underpinned 
by the eAIMS.
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Figure 4 Time- and- motion study showing the estimated time managing an individual adrenal incidentaloma case for each 
of the phases of the process: (I) pre- intervention, (II) eAIMS implementation with case prioritisation and (III) proactive case 
identification and streamlining into low- risk and high- risk groups. eAIMS, electronic Adrenal Incidentaloma Management 
System; MDT, multidisciplinary team.
An independent health economic assessment, led by 
the University of East Anglia, assessed the hands- on time 
of clinical staff at three phases. Phase I was prior to the 
project implementation. Phase II was the time period 
following implementation of the multidisciplinary team 
prioritisation process and the eAIMS go- live. The final 
phase, phase III, is the proactive adrenal incidentaloma 
identification and case streamlining process (post- project 
phase currently being implemented).
The impact of these phases (figure 4) showed that the 
estimated cumulative time taken for progressing each 
case was: phase I, 168 min; phase II, 115 min; and phase 
III, 66 min.
The cost impact of this phased change was then eval-
uated using standardised staff costs, in conjunction with 
a novel Adrenal Incidentaloma Intervention Cost Assess-
ment Tool. This analysis showed that the combination 
of using a multidisciplinary team prioritisation process 
and introduction of the eAIMS (phase II) significantly 
reduced the number of steps and tasks in the patient 
management process, the total time taken (from adrenal 
incidentaloma identification to multidisciplinary team 
decision) by 48.6% and the total costs associated with 
treating each patient by 28.2%.
As a result of the focus group discussions, we devel-
oped a simple patient leaflet. We will hold further focus 
groups on both sites to review this and include frequently 
asked questions. These will be uploaded onto eAIMS on a 
patient- accessible section for online support.
lessons and limiTaTions
evolution of our understanding of the financial impact
The time taken to progress a case through the system 
from identification until multidisciplinary team decision 
was costed, using standardised NHS costs for both admin-
istrative and clinical time.
The total cost per case was then evaluated, comparing 
phase I (pre- project) against phase II (the implemented 
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project, with eAIMS implementation and prioritisation 
process).
However, we have always been focused on the fact that 
a key deliverable was the identification of all adrenal inci-
dentaloma cases. Even with a dedicated well- publicised 
multidisciplinary team, only 30% of University Hospi-
tals of North Midlands’s adrenal incidentalomas were 
referred. We have therefore developed our practices to 
allow us to streamline the process even further to enable 
the handling of more cases in a cost- effective manner. 
Our projected (phase III) figures are encouraging. These 
will be formally evaluated, using the specifically designed 
adrenal incidentaloma cost attribution tool.
calculation of the cost of the intervention
To facilitate the development of a web- based system 
within the tight time frame of the project, we had to 
appoint a dedicated IT programmer. This meant we had 
to change the original costing allocations awarded by the 
funder, the Health Foundation. This was shared with, and 
approved by, the funder early on.
implementation costs
Quality Improvement projects often struggle with finan-
cial hurdles on implementation. We were pleased that 
phase II evolved seamlessly and no additional cost impli-
cations to the grant arose. This was facilitated by the fact 
that the Trust noted the additional workload created by 
the adrenal incidentaloma project and appointed an 
additional band four multidisciplinary team co- ordinator 
(this could be viewed as a positive balancing measure).
commissioning challenges
Each patient with adrenal incidentaloma referred to us is 
costed as a new case, as per an agreement with the Clin-
ical Commissioning Group.
Based on our data (that we receive only 30% of patients 
with adrenal incidentaloma as referrals) and the projected 
surge in adrenal incidentaloma cases to be identified and 
processed (~500 cases per annum in our Trust, projected 
to an estimated 50 000 cases per annum across the UK), 
we are engaging the service commissioners to agree the 
most suitable and cost- effective way to manage these cases.
The system we have developed (eAIMS) will enable us 
to detect all these missed cases. We can highlight them 
to their general practitioners and, if they wish, we will 
process them efficiently through our streamlined multi-
disciplinary team process and electronic management 
system. Our system and pathway will handle more cases 
within the existing budget limitations, given the more 
streamlined and efficient approach, while also removing 
waste and enhancing safety. We are engaging with other 
Trusts, and with national professional bodies, to facilitate 
wider uptake and spread of our patient management 
processes. This could also be the beginning of a national 
registry that will, in the future, form the evidence- based 
data required to inform further guideline development.
endocrinology engagement/capacity
Endocrinology colleagues could fear being swamped by 
the many extra, proactively identified, adrenal inciden-
talomas that were previously missed or lost in the system. 
Our approach, using eAIMS, has been confirmed to reduce 
the time spent per patient, with a corresponding reduced 
cost. We shared this with a cohort of our colleagues in 
the Autumn meeting of the Association of British Clinical 
Diabetologists (London, November 2017). This was well 
received, with many clinicians indicating that the process 
improvements were necessary to enable clinicians to cope 
with the workload. Many clinicians were appreciative of 
the patient support approach and indicated they would 
consider supporting the management of their patients 
using such an approach.
conclusion
Faced with the challenge of increasing adrenal inciden-
taloma patient workload, together with limited guidance 
on how to manage these cases effectively, we undertook 
this quality improvement initiative.
First, we re- designed the adrenal incidentaloma clin-
ical management pathway, developing a prioritisation 
strategy, in collaboration with radiology and biochem-
istry multidisciplinary team members. This ensured that 
high- risk individuals were prioritised for detailed prompt 
discussions, while streamlining the process for low- risk 
cases.
We also developed a web- based patient management 
system (eAIMS). This captures the key information on 
all adrenal incidentaloma cases and generates a pre- 
populated outcome letter, saving both clinical and 
administrative time and effort while ensuring a timely 
management plan with enhanced safety (reduced need 
to re- dictate and type, thereby minimising transcription 
errors). The system is aligned with the recently published 
European guidelines for adrenal incidentaloma 
management.
The eAIMS system and multidisciplinary team process 
will enable detection of previously missed adrenal inci-
dentaloma cases, of which 20% could be hormonally 
active or malignant. These cases can be highlighted to 
general practitioners. The additional workload would 
be circumvented by the implementation of the more 
efficient and streamlined process, underpinned by the 
eAIMS system.
We gathered patients’ views to inform the process 
mapping, helping to re- design the multidisciplinary team 
process to address the concerns expressed in our focus 
group discussion. Patient views also helped develop an 
information leaflet.
We have an established partnership with University 
Hospital of South Manchester. We used this to demon-
strate the generalisability of the utility of the system. The 
system was conceived as web- based from conception to 
facilitate wider adoption.
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